Abstract
Improved treatments for heart failure patients will require the development of novel therapeutic strategies that target basal disease mechanisms. Disrupted cardiomyocyte Ca2+ homeostasis is recognized as a major contributor to the heart failure phenotype, as it plays a key role in systolic and diastolic dysfunction, arrhythmogenesis, and hypertrophy and apoptosis signaling. In this review, we outline existing knowledge of the involvement of Ca2+ homeostasis in these deficits, and identify four promising targets for therapeutic intervention: the sarcoplasmic reticulum Ca2+ ATPase, the Na+-Ca2+ exchanger, the ryanodine receptor, and t-tubule structure. We discuss experimental data indicating the applicability of these targets that has led to recent and ongoing clinical trials, and suggest future therapeutic approaches.
Keywords: Cardiac myocytes, calcium homeostasis, heart failure, SR Ca2+ ATPase, Na+/Ca2+ exchanger, ryanodine receptor, t-tubules.
Current Pharmaceutical Design
Title:Targeting Cardiomyocyte Ca2+ Homeostasis in Heart Failure
Volume: 21 Issue: 4
Author(s): Asmund T. Roe, Michael Frisk and William E. Louch
Affiliation:
Keywords: Cardiac myocytes, calcium homeostasis, heart failure, SR Ca2+ ATPase, Na+/Ca2+ exchanger, ryanodine receptor, t-tubules.
Abstract: Improved treatments for heart failure patients will require the development of novel therapeutic strategies that target basal disease mechanisms. Disrupted cardiomyocyte Ca2+ homeostasis is recognized as a major contributor to the heart failure phenotype, as it plays a key role in systolic and diastolic dysfunction, arrhythmogenesis, and hypertrophy and apoptosis signaling. In this review, we outline existing knowledge of the involvement of Ca2+ homeostasis in these deficits, and identify four promising targets for therapeutic intervention: the sarcoplasmic reticulum Ca2+ ATPase, the Na+-Ca2+ exchanger, the ryanodine receptor, and t-tubule structure. We discuss experimental data indicating the applicability of these targets that has led to recent and ongoing clinical trials, and suggest future therapeutic approaches.
Export Options
About this article
Cite this article as:
Roe T. Asmund, Frisk Michael and Louch E. William, Targeting Cardiomyocyte Ca2+ Homeostasis in Heart Failure, Current Pharmaceutical Design 2015; 21 (4) . https://dx.doi.org/10.2174/138161282104141204124129
DOI https://dx.doi.org/10.2174/138161282104141204124129 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Platelet Biomarkers in Tumor Growth
Current Proteomics Post-traumatic Stress Disorder in Heart Failure Patients: A Test of the Cardiac Disease-induced PTSD Hypothesis
Current Psychiatry Research and Reviews Gender Differences in Non-Obstructive Coronary Artery Disease
Current Pharmaceutical Design Hedgehog Signaling and Urological Cancers
Current Drug Targets Proton Ion-Microbeam Elemental Analysis for Inhaled Particle-Induced Pulmonary Diseases: Application for Diagnosis and Assessment of Progression
Current Medicinal Chemistry Apoptotic Cell Clearance and Autoimmune Disorder
Current Medicinal Chemistry A Pharmacological Primer of Biased Agonism
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Colchicine in Pericardial Syndromes
Current Pharmaceutical Design Cryptotanshinone Induces Pro-death Autophagy through JNK Signaling Mediated by Reactive Oxygen Species Generation in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Structural and Functional Characterization of a Mutant of Pseudocerastes persicus Natriuretic Peptide
Protein & Peptide Letters Monoclonal Antibody-based Genetic Immunotherapy
Current Gene Therapy Neuroprotective Effects of <i>Nardostachys jatamansi</i> Against BSO Induced Anxiety via its Antioxidant Machinery and by Elevating Catecholamines and GABA levels in Mice
Current Traditional Medicine Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design Microvascular Obstruction After Primary Percutaneous Coronary Intervention: Pathogenesis, Diagnosis and Prognostic Significance
Current Vascular Pharmacology Polyunsaturated Fatty Acids and Cardiovascular Disease
Current Pharmaceutical Design Multiple Pharmacological Properties of a Novel Parthenin Analog P16 as Evident by its Cytostatic and Antiangiogenic Potential Against Pancreatic Adenocarcinoma PANC -1 Cells
Anti-Cancer Agents in Medicinal Chemistry Endothelin-1 and Human Platelets
Current Vascular Pharmacology miR-25 Mediates Retinal Degeneration Via Inhibiting ITGAV and PEDF in Rat
Current Molecular Medicine Nitric Oxide Pathway as New Drug Targets for Refractory Hypertension
Current Pharmaceutical Design